
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX Inc. is demonstrating a robust outlook amid favorable clinical trial results for its therapeutic candidates, BX211 and BX011, with significant improvements noted across multiple parameters related to diabetic foot osteomyelitis and chronic pulmonary infections. Positive feedback from the FDA regarding the advancement of BX011 into a Phase 2a study underscores the potential for enhanced efficacy in treating conditions like diabetic foot infections and suggests a promising regulatory pathway. The company’s innovative BOLT platform, combined with ongoing clinical advancements, suggests opportunities for higher market penetration and a broader indication base, contributing positively to BiomX's future financial performance.
Bears say
BiomX Inc. faces significant challenges that have led to a negative outlook on its stock, primarily due to investor sentiment surrounding its clinical trial results. The statistical significance of key endpoints was a concern, particularly as some metrics, such as the week 13 PAR, narrowly missed the conventional threshold, signaling potential issues in the efficacy of its products. Additionally, risks related to failed clinical trials, difficulties in securing adequate funding, and the possibility of dilutive capital raises further contribute to a foreboding financial outlook for the company.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares